These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30549344)

  • 1. Role and regulation of proapoptotic Bax in oral squamous cell carcinoma and drug resistance.
    Alam M; Kashyap T; Mishra P; Panda AK; Nagini S; Mishra R
    Head Neck; 2019 Jan; 41(1):185-197. PubMed ID: 30549344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bcl-xL expression and regulation in the progression, recurrence, and cisplatin resistance of oral cancer.
    Alam M; Mishra R
    Life Sci; 2021 Sep; 280():119705. PubMed ID: 34111459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crosstalk between Raf-MEK-ERK and PI3K-Akt-GSK3β signaling networks promotes chemoresistance, invasion/migration and stemness via expression of CD44 variants (v4 and v6) in oral cancer.
    Kashyap T; Pramanik KK; Nath N; Mishra P; Singh AK; Nagini S; Rana A; Mishra R
    Oral Oncol; 2018 Nov; 86():234-243. PubMed ID: 30409306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The elevated activation of NFκB and AP-1 is correlated with differential regulation of Bcl-2 and associated with oral squamous cell carcinoma progression and resistance.
    Alam M; Kashyap T; Pramanik KK; Singh AK; Nagini S; Mishra R
    Clin Oral Investig; 2017 Dec; 21(9):2721-2731. PubMed ID: 28233171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Up-regulation of survivin in oral squamous cell carcinoma correlates with poor prognosis and chemoresistance.
    Su L; Wang Y; Xiao M; Lin Y; Yu L
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Oct; 110(4):484-91. PubMed ID: 20868995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of BCL-2 in the progression of oral cancer is not attributable to mutations.
    Loro LL; Johannessen AC; Vintermyr OK
    J Clin Pathol; 2005 Nov; 58(11):1157-62. PubMed ID: 16254104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of Bcl-xL, Bax, and p53 in primary tumors and lymph node metastases in oral squamous cell carcinoma.
    Baltaziak M; Duraj E; Koda M; Wincewicz A; Musiatowicz M; Kanczuga-Koda L; Szymanska M; Lesniewicz T; Musiatowicz B
    Ann N Y Acad Sci; 2006 Dec; 1090():18-25. PubMed ID: 17384243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of bcl-2 and bax in chewing tobacco-induced oral cancers and oral lesions from India.
    Teni T; Pawar S; Sanghvi V; Saranath D
    Pathol Oncol Res; 2002; 8(2):109-14. PubMed ID: 12172574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycogen synthase kinase-3β mediated regulation of matrix metalloproteinase-9 and its involvement in oral squamous cell carcinoma progression and invasion.
    Pramanik KK; Nagini S; Singh AK; Mishra P; Kashyap T; Nath N; Alam M; Rana A; Mishra R
    Cell Oncol (Dordr); 2018 Feb; 41(1):47-60. PubMed ID: 29134466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role and regulation of GLUT1/3 during oral cancer progression and therapy resistance.
    Kumari A; Jha A; Tiwari A; Nath N; Kumar A; Nagini S; Mishra R
    Arch Oral Biol; 2023 Jun; 150():105688. PubMed ID: 36989865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bax expression measured by AQUAnalysis is an independent prognostic marker in oral squamous cell carcinoma.
    Bose P; Klimowicz AC; Kornaga E; Petrillo SK; Matthews TW; Chandarana S; Magliocco AM; Brockton NT; Dort JC
    BMC Cancer; 2012 Aug; 12():332. PubMed ID: 22852863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of Tumor Suppressor CYLD Expression Triggers Cisplatin Resistance in Oral Squamous Cell Carcinoma.
    Suenaga N; Kuramitsu M; Komure K; Kanemaru A; Takano K; Ozeki K; Nishimura Y; Yoshida R; Nakayama H; Shinriki S; Saito H; Jono H
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31635163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exosomes containing miR-21 transfer the characteristic of cisplatin resistance by targeting PTEN and PDCD4 in oral squamous cell carcinoma.
    Liu T; Chen G; Sun D; Lei M; Li Y; Zhou C; Li X; Xue W; Wang H; Liu C; Xu J
    Acta Biochim Biophys Sin (Shanghai); 2017 Sep; 49(9):808-816. PubMed ID: 28910982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
    Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
    Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant promoter hypermethylation of the CHFR gene in oral squamous cell carcinomas.
    Baba S; Hara A; Kato K; Long NK; Hatano Y; Kimura M; Okano Y; Yamada Y; Shibata T
    Oncol Rep; 2009 Nov; 22(5):1173-9. PubMed ID: 19787237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nimbolide, a neem limonoid inhibits cytoprotective autophagy to activate apoptosis via modulation of the PI3K/Akt/GSK-3β signalling pathway in oral cancer.
    Sophia J; Kowshik J; Dwivedi A; Bhutia SK; Manavathi B; Mishra R; Nagini S
    Cell Death Dis; 2018 Oct; 9(11):1087. PubMed ID: 30352996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p22phox confers resistance to cisplatin, by blocking its entry into the nucleus.
    Hung CC; Chien CY; Chiang WF; Lin CS; Hour TC; Chen HR; Wang LF; Ko JY; Chang CH; Chen JY
    Oncotarget; 2015 Feb; 6(6):4110-25. PubMed ID: 25686830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of T-cadherin inhibits the proliferation of oral squamous cell carcinoma through the PI3K/AKT/mTOR intracellular signalling pathway.
    Wang Q; Zhang X; Song X; Zhang L
    Arch Oral Biol; 2018 Dec; 96():74-79. PubMed ID: 30195142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apoptosis and expression of Bax and Bcl-2 in snuff- and non-snuff associated oral squamous cell carcinomas.
    Loro LL; Vintermyr OK; Ibrahim SO; Idris AM; Johannessen AC
    Anticancer Res; 2000; 20(5A):2855-60. PubMed ID: 11062693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The human HECA interacts with cyclins and CDKs to antagonize Wnt-mediated proliferation and chemoresistance of head and neck cancer cells.
    Dowejko A; Bauer R; Bauer K; Müller-Richter UD; Reichert TE
    Exp Cell Res; 2012 Mar; 318(5):489-99. PubMed ID: 22100912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.